{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T16:31:31Z","timestamp":1786120291894,"version":"build-2736575974"},"reference-count":70,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2012,1]]},"DOI":"10.1097\/bor.0b013e32834d5730","type":"journal-article","created":{"date-parts":[[2011,11,16]],"date-time":"2011-11-16T01:39:44Z","timestamp":1321407584000},"page":"15-23","source":"Crossref","is-referenced-by-count":39,"title":["Treatment of antineutrophil cytoplasmic antibody-associated vasculitis with rituximab"],"prefix":"10.1097","volume":"24","author":[{"given":"Rodrigo","family":"Cartin-Ceba","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fernando C.","family":"Fervenza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulrich","family":"Specks","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-4-20210128","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1002\/art.1780370206","article-title":"Nomenclature of systemic vasculitides. Proposal of an international consensus conference.","volume":"37","author":"Jennette","year":"1994","journal-title":"Arthritis Rheum"},{"key":"R2-4-20210128","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1002\/1529-0131(199904)42:3<421::AID-ANR5>3.0.CO;2-6","article-title":"Microscopic polyangiitis: clinical and laboratory findings in eighty-five patients.","volume":"42","author":"Guillevin","year":"1999","journal-title":"Arthritis Rheum"},{"key":"R3-4-20210128","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1016\/S0002-9343(03)00359-0","article-title":"Churg-Strauss syndrome: clinical presentation, antineutrophil cytoplasmic antibodies, and leukotriene receptor antagonists.","volume":"115","author":"Keogh","year":"2003","journal-title":"Am J Med"},{"key":"R5-4-20210128","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1002\/1529-0131(199809)41:9<1521::AID-ART2>3.0.CO;2-A","article-title":"Antineutrophil cytoplasmic antibodies.","volume":"41","author":"Hoffman","year":"1998","journal-title":"Arthritis Rheum"},{"key":"R6-4-20210128","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1056\/NEJMoa020286","article-title":"A randomized trial of maintenance therapy for vasculitis associated with antineutrophil cytoplasmic autoantibodies.","volume":"349","author":"Jayne","year":"2003","journal-title":"N Engl J Med"},{"key":"R7-4-20210128","doi-asserted-by":"crossref","first-page":"2461","DOI":"10.1002\/art.21142","article-title":"Randomized trial of cyclophosphamide versus methotrexate for induction of remission in early systemic antineutrophil cytoplasmic antibody-associated vasculitis.","volume":"52","author":"De Groot","year":"2005","journal-title":"Arthritis Rheum"},{"key":"R8-4-20210128","doi-asserted-by":"crossref","first-page":"2180","DOI":"10.1681\/ASN.2007010090","article-title":"Randomized trial of plasma exchange or high-dosage methylprednisolone as adjunctive therapy for severe renal vasculitis.","volume":"18","author":"Jayne","year":"2007","journal-title":"J Am Soc Nephrol"},{"key":"R9-4-20210128","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1056\/NEJMoa0909169","article-title":"Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis.","volume":"363","author":"Jones","year":"2010","journal-title":"N Engl J Med"},{"key":"R10-4-20210128","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1056\/NEJMoa0909905","article-title":"Rituximab versus cyclophosphamide for ANCA-associated vasculitis.","volume":"363","author":"Stone","year":"2010","journal-title":"N Engl J Med"},{"key":"R11-4-20210128","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1136\/bmj.2.5091.265","article-title":"Giant-cell granuloma of the respiratory tract (Wegeners granulomatosis).","volume":"2","author":"Walton","year":"1958","journal-title":"Br Med J"},{"key":"R12-4-20210128","doi-asserted-by":"crossref","first-page":"76","DOI":"10.7326\/0003-4819-98-1-76","article-title":"Wegeners granulomatosis: prospective clinical and therapeutic experience with 85 patients for 21 years.","volume":"98","author":"Fauci","year":"1983","journal-title":"Ann Intern Med"},{"key":"R13-4-20210128","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1681\/ASN.V7133","article-title":"Treatment response and relapse in antineutrophil cytoplasmic autoantibody-associated microscopic polyangiitis and glomerulonephritis.","volume":"7","author":"Nachman","year":"1996","journal-title":"J Am Soc Nephrol"},{"key":"R14-4-20210128","doi-asserted-by":"crossref","first-page":"488","DOI":"10.7326\/0003-4819-116-6-488","article-title":"Wegener granulomatosis: an analysis of 158 patients.","volume":"116","author":"Hoffman","year":"1992","journal-title":"Ann Intern Med"},{"key":"R15-4-20210128","doi-asserted-by":"crossref","first-page":"477","DOI":"10.7326\/0003-4819-124-5-199603010-00003","article-title":"Cyclophosphamide-induced cystitis and bladder cancer in patients with Wegener granulomatosis.","volume":"124","author":"Talar-Williams","year":"1996","journal-title":"Ann Intern Med"},{"key":"R16-4-20210128","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1002\/art.1780380505","article-title":"An analysis of forty-two Wegeners granulomatosis patients treated with methotrexate and prednisone.","volume":"38","author":"Sneller","year":"1995","journal-title":"Arthritis Rheum"},{"key":"R17-4-20210128","doi-asserted-by":"crossref","first-page":"2666","DOI":"10.1002\/1529-0131(199912)42:12<2666::AID-ANR24>3.0.CO;2-E","article-title":"A staged approach to the treatment of Wegeners granulomatosis: induction of remission with glucocorticoids and daily cyclophosphamide switching to methotrexate for remission maintenance.","volume":"42","author":"Langford","year":"1999","journal-title":"Arthritis Rheum"},{"key":"R18-4-20210128","doi-asserted-by":"crossref","first-page":"2836","DOI":"10.1002\/1529-0131(200112)44:12<2836::AID-ART471>3.0.CO;2-W","article-title":"Response of Wegeners granulomatosis to anti-CD20 chimeric monoclonal antibody therapy.","volume":"44","author":"Specks","year":"2001","journal-title":"Arthritis Rheum"},{"key":"R19-4-20210128","doi-asserted-by":"crossref","first-page":"2453","DOI":"10.4049\/jimmunol.128.6.2453","article-title":"Suppression of human B lymphocyte function by cyclophosphamide.","volume":"128","author":"Cupps","year":"1982","journal-title":"J Immunol"},{"key":"R20-4-20210128","first-page":"391","article-title":"Activation of human B lymphocytes. XII. Differential effects of in vitro cyclophosphamide on human lymphocyte subpopulations involved in B-cell activation.","volume":"39","author":"Stevenson","year":"1980","journal-title":"Immunology"},{"key":"R21-4-20210128","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1016\/S0091-6749(99)70434-3","article-title":"Differential B- and T-cell activation in Wegeners granulomatosis.","volume":"103","author":"Popa","year":"1999","journal-title":"J Allergy Clin Immunol"},{"key":"R22-4-20210128","first-page":"9","article-title":"Rituximab: an insiders historical perspective.","volume":"27","author":"Grillo-Lopez","year":"2000","journal-title":"Semin Oncol"},{"key":"R23-4-20210128","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1002\/j.1460-2075.1988.tb02867.x","article-title":"Molecular cloning of the human B cell CD20 receptor predicts a hydrophobic protein with multiple transmembrane domains.","volume":"7","author":"Einfeld","year":"1988","journal-title":"EMBO J"},{"key":"R24-4-20210128","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1016\/0167-5699(94)90276-3","article-title":"CD20: a regulator of cell-cycle progression of B lymphocytes.","volume":"15","author":"Tedder","year":"1994","journal-title":"Immunol Today"},{"key":"R25-4-20210128","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1089\/cbr.1997.12.177","article-title":"Chimeric anti-CD20 (IDEC-C2B8) monoclonal antibody sensitizes a B cell lymphoma cell line to cell killing by cytotoxic drugs.","volume":"12","author":"Demidem","year":"1997","journal-title":"Cancer Biother Radiopharm"},{"key":"R26-4-20210128","doi-asserted-by":"crossref","first-page":"3900","DOI":"10.1182\/blood.V95.12.3900.012k14_3900_3908","article-title":"Biologic response of B lymphoma cells to anti-CD20 monoclonal antibody rituximab in vitro: CD55 and CD59 regulate complement-mediated cell lysis.","volume":"95","author":"Golay","year":"2000","journal-title":"Blood"},{"key":"R27-4-20210128","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1007\/s002620050016","article-title":"Signaling events involved in anti-CD20-induced apoptosis of malignant human B cells.","volume":"48","author":"Shan","year":"2000","journal-title":"Cancer Immunol Immunother"},{"key":"R28-4-20210128","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1053\/sonc.2003.50025","article-title":"The mechanisms of action of rituximab in the elimination of tumor cells.","volume":"30","author":"Johnson","year":"2003","journal-title":"Semin Oncol"},{"key":"R29-4-20210128","doi-asserted-by":"crossref","first-page":"1659","DOI":"10.1084\/jem.20040119","article-title":"The innate mononuclear phagocyte network depletes B lymphocytes through Fc receptor-dependent mechanisms during anti-CD20 antibody immunotherapy.","volume":"199","author":"Uchida","year":"2004","journal-title":"J Exp Med"},{"key":"R30-4-20210128","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.clim.2005.08.006","article-title":"The therapeutic potential of anti-CD20 what do B-cells do.","volume":"117","author":"Eisenberg","year":"2005","journal-title":"Clin Immunol"},{"key":"R31-4-20210128","doi-asserted-by":"crossref","first-page":"3580","DOI":"10.1002\/art.20592","article-title":"Rituximab improves peripheral B cell abnormalities in human systemic lupus erythematosus.","volume":"50","author":"Anolik","year":"2004","journal-title":"Arthritis Rheum"},{"key":"R32-4-20210128","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1002\/art.20718","article-title":"Induction of remission by B lymphocyte depletion in eleven patients with refractory antineutrophil cytoplasmic antibody-associated vasculitis.","volume":"52","author":"Keogh","year":"2005","journal-title":"Arthritis Rheum"},{"key":"R33-4-20210128","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1164\/rccm.200507-1144OC","article-title":"Rituximab for refractory Wegeners granulomatosis: report of a prospective, open-label pilot trial.","volume":"173","author":"Keogh","year":"2006","journal-title":"Am J Respir Crit Care Med"},{"key":"R34-4-20210128","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1111\/j.1365-2796.2005.01494.x","article-title":"Nine patients with antineutrophil cytoplasmic antibody-positive vasculitis successfully treated with rituximab.","volume":"257","author":"Eriksson","year":"2005","journal-title":"J Intern Med"},{"key":"R35-4-20210128","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1080\/02813430510015269","article-title":"Anti-CD20 therapy of treatment-resistant Wegeners granulomatosis: favourable but temporary response.","volume":"34","author":"Omdal","year":"2005","journal-title":"Scand J Rheumatol"},{"key":"R36-4-20210128","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1136\/ard.2005.044420","article-title":"Lack of efficacy of rituximab in Wegeners granulomatosis with refractory granulomatous manifestations.","volume":"65","author":"Aries","year":"2006","journal-title":"Ann Rheum Dis"},{"key":"R37-4-20210128","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1136\/ard.2004.029694","article-title":"Tolerance and short term efficacy of rituximab in 43 patients with systemic autoimmune diseases.","volume":"64","author":"Gottenberg","year":"2005","journal-title":"Ann Rheum Dis"},{"key":"R38-4-20210128","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1093\/rheumatology\/kel098","article-title":"Long-term observation of patients with antineutrophil cytoplasmic antibody-associated vasculitis treated with rituximab.","volume":"45","author":"Stasi","year":"2006","journal-title":"Rheumatology (Oxford)"},{"key":"R39-4-20210128","doi-asserted-by":"crossref","first-page":"2970","DOI":"10.1002\/art.22046","article-title":"Long-term comparison of rituximab treatment for refractory systemic lupus erythematosus and vasculitis: Remission, relapse, and re-treatment.","volume":"54","author":"Smith","year":"2006","journal-title":"Arthritis Rheum"},{"key":"R40-4-20210128","first-page":"S23","article-title":"Adjunction of rituximab to steroids and immunosuppressants for refractoryrelapsing Wegeners granulomatosis: a study on 8 patients.","volume":"25","author":"Brihaye","year":"2007","journal-title":"Clin Exp Rheumatol"},{"key":"R41-4-20210128","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1007\/s10067-007-0643-9","article-title":"Rituximab for treatment-resistant extensive Wegeners granulomatosis-additive effects of a maintenance treatment with leflunomide.","volume":"26","author":"Henes","year":"2007","journal-title":"Clin Rheumatol"},{"key":"R42-4-20210128","first-page":"458","article-title":"Rituximab for treatment of patients with systemic autoimmune diseases.","volume":"128","author":"Garcia Hernandez","year":"2007","journal-title":"Med Clin (Barc)"},{"key":"R43-4-20210128","first-page":"468","article-title":"Off-label use of rituximab in 196 patients with severe, refractory systemic autoimmune diseases.","volume":"28","author":"Ramos-Casals","year":"2010","journal-title":"Clin Exp Rheumatol"},{"key":"R44-4-20210128","first-page":"2017","article-title":"Efficacy of rituximab in limited Wegeners granulomatosis with refractory granulomatous manifestations.","volume":"35","author":"Seo","year":"2008","journal-title":"J Rheumatol"},{"key":"R45-4-20210128","doi-asserted-by":"crossref","first-page":"409","DOI":"10.2169\/internalmedicine.46.6156","article-title":"Two cases of refractory Wegeners granulomatosis successfully treated with rituximab.","volume":"46","author":"Tamura","year":"2007","journal-title":"Intern Med"},{"key":"R47-4-20210128","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1097\/RHU.0b013e31816b4487","article-title":"Effect of rituximab on refractory Wegener granulomatosis with predominant granulomatous disease.","volume":"14","author":"Sanchez-Cano","year":"2008","journal-title":"J Clin Rheumatol"},{"key":"R48-4-20210128","first-page":"S67","article-title":"Effects of anti-CD20 monoclonal antibody as a rescue treatment for ANCA-associated idiopathic systemic vasculitis with or without overt renal involvement.","volume":"26","author":"Roccatello","year":"2008","journal-title":"Clin Exp Rheumatol"},{"key":"R49-4-20210128","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1093\/ndt\/gfn430","article-title":"Rituximab as rescue therapy in antineutrophil cytoplasmic antibody-associated vasculitis: a single-centre experience with 15 patients.","volume":"24","author":"Lovric","year":"2009","journal-title":"Nephrol Dial Transplant"},{"key":"R50-4-20210128","doi-asserted-by":"crossref","first-page":"2156","DOI":"10.1002\/art.24637","article-title":"A multicenter survey of rituximab therapy for refractory antineutrophil cytoplasmic antibody-associated vasculitis.","volume":"60","author":"Jones","year":"2009","journal-title":"Arthritis Rheum"},{"key":"R51-4-20210128","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1093\/rheumatology\/kep148","article-title":"Biologic therapy in primary systemic vasculitis of the young.","volume":"48","author":"Eleftheriou","year":"2009","journal-title":"Rheumatology (Oxford)"},{"key":"R52-4-20210128","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1002\/art.24454","article-title":"Rituximab is effective in the treatment of refractory ophthalmic Wegeners granulomatosis.","volume":"60","author":"Taylor","year":"2009","journal-title":"Arthritis Rheum"},{"key":"R53-4-20210128","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1159\/000329535","article-title":"Long-term effects of rituximab added to cyclophosphamide in refractory patients with vasculitis.","volume":"34","author":"Roccatello","year":"2011","journal-title":"Am J Nephrol"},{"key":"R54-4-20210128","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1136\/ard.2008.097758","article-title":"Comparison of disease activity measures for antineutrophil cytoplasmic autoantibody (ANCA)-associated vasculitis.","volume":"68","author":"Merkel","year":"2009","journal-title":"Ann Rheum Dis"},{"issue":"Suppl 1","key":"R55-4-20210128","first-page":"65","article-title":"RAVE Research GroupLong-term efficacy and safety results of the RAVE trial abstract.","volume":"164","author":"Specks","year":"2011","journal-title":"Clin Exp Immunol"},{"key":"R56-4-20210128","doi-asserted-by":"crossref","first-page":"1394","DOI":"10.2215\/CJN.08821209","article-title":"Rituximab as maintenance therapy for antineutrophil cytoplasmic antibody-associated vasculitis.","volume":"5","author":"Rhee","year":"2010","journal-title":"Clin J Am Soc Nephrol"},{"key":"R57-4-20210128","first-page":"S83","article-title":"Protocolised versus nonprotocolised rituximab treatment for refractory ANCA-associated vasculitis.","volume":"62","author":"Jones","year":"2010","journal-title":"Arthritis Rheum"},{"key":"R58-4-20210128","first-page":"S283","article-title":"Rituximab for remission induction and maintenance in ANCA-associated vasculitis: a single center ten-year experience in 108 patients.","volume":"62","author":"Cartin-Ceba","year":"2010","journal-title":"Arthritis Rheum"},{"key":"R59-4-20210128","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1136\/ard.2008.093773","article-title":"Severe bronchospasm associated with rituximab for refractory Churg-Strauss syndrome.","volume":"68","author":"Bouldouyre","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"R60-4-20210128","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1007\/s00296-009-1146-6","article-title":"Churg-Strauss syndrome successfully treated with rituximab.","volume":"31","author":"Donvik","year":"2010","journal-title":"Rheumatol Int"},{"key":"R61-4-20210128","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1136\/ard.2005.047308","article-title":"Successful use of rituximab in a patient with recalcitrant Churg-Strauss syndrome.","volume":"65","author":"Kaushik","year":"2006","journal-title":"Ann Rheum Dis"},{"key":"R62-4-20210128","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/ard.2005.042937","article-title":"Rituximab in Churg-Strauss syndrome.","volume":"65","author":"Koukoulaki","year":"2006","journal-title":"Ann Rheum Dis"},{"key":"R63-4-20210128","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1093\/rheumatology\/ken175","article-title":"Rituximab is effective in the treatment of refractory Churg-Strauss syndrome and is associated with diminished T-cell interleukin-5 production.","volume":"47","author":"Pepper","year":"2008","journal-title":"Rheumatology (Oxford)"},{"key":"R64-4-20210128","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1136\/ard.2009.109850","article-title":"Successful use of rituximab in a patient with Churg-Strauss syndrome and refractory central nervous system involvement.","volume":"69","author":"Saech","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"R65-4-20210128","doi-asserted-by":"crossref","first-page":"2865","DOI":"10.1093\/ndt\/gfq852","article-title":"Rituximab for the treatment of Churg-Strauss syndrome with renal involvement.","volume":"26","author":"Cartin-Ceba","year":"2011","journal-title":"Nephrol Dial Transplant"},{"key":"R66-4-20210128","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1007\/s00277-004-0899-y","article-title":"Delayed hepatitis B virus reactivation after cessation of preemptive lamivudine in lymphoma patients treated with rituximab plus CHOP.","volume":"83","author":"Dai","year":"2004","journal-title":"Ann Hematol"},{"key":"R67-4-20210128","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1080\/1042819031000151923","article-title":"Hepatitis B virus reactivation in a case of non-Hodgkins lymphoma treated with chemotherapy and rituximab: necessity of prophylaxis for hepatitis B virus reactivation in rituximab therapy.","volume":"45","author":"Tsutsumi","year":"2004","journal-title":"Leuk Lymphoma"},{"key":"R68-4-20210128","doi-asserted-by":"crossref","first-page":"68","DOI":"10.5414\/NPP26068","article-title":"Progressive multifocal leukoencephalopathy in a lymphoma patient with complete remission after treatment with cytostatics and rituximab: case report and review of the literature.","volume":"26","author":"Freim Wahl","year":"2007","journal-title":"Clin Neuropathol"},{"key":"R69-4-20210128","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1002\/ajh.20492","article-title":"Changes in the natural history of progressive multifocal leukoencephalopathy in HIV-negative lymphoproliferative disorders: impact of novel therapies.","volume":"80","author":"Garcia-Suarez","year":"2005","journal-title":"Am J Hematol"},{"key":"R70-4-20210128","doi-asserted-by":"crossref","first-page":"4834","DOI":"10.1182\/blood-2008-10-186999","article-title":"Progressive multifocal leukoencephalopathy after rituximab therapy in HIV-negative patients: a report of 57 cases from the Research on Adverse Drug Events and Reports project.","volume":"113","author":"Carson","year":"2009","journal-title":"Blood"},{"key":"R71-4-20210128","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/S1474-4422(10)70040-5","article-title":"Progressive multifocal leukoencephalopathy and other disorders caused by JC virus: clinical features and pathogenesis.","volume":"9","author":"Tan","year":"2010","journal-title":"Lancet Neurol"},{"key":"R72-4-20210128","doi-asserted-by":"crossref","first-page":"2209","DOI":"10.1002\/art.30427","article-title":"Late-onset neutropenia following rituximab therapy in rheumatic diseases: association with B lymphocyte depletion and infections.","volume":"63","author":"Tesfa","year":"2011","journal-title":"Arthritis Rheum"}],"container-title":["Current Opinion in Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/BOR.0b013e32834d5730","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T20:27:47Z","timestamp":1786048067000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00002281-201201000-00004"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,1]]},"references-count":70,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2012]]}},"URL":"https:\/\/doi.org\/10.1097\/bor.0b013e32834d5730","relation":{},"ISSN":["1040-8711"],"issn-type":[{"value":"1040-8711","type":"print"}],"subject":[],"published":{"date-parts":[[2012,1]]}}}